Cagrilintide and CagriSema
Explore peptide research and guides on cagrilintide and cagrisema.
Cagrilintide and CagriSema
Cagrilintide: The Amylin Half of CagriSema
Cagrilintide is a long-acting amylin analog engineered for once-weekly dosing. It produced 20.4% weight loss combined with semaglutide in the REDEFINE trials.
Cagrilintide and CagriSemaCombination Peptide Therapy: Two Mechanisms vs One
CagriSema, tirzepatide, and triple agonists combine peptide pathways for greater metabolic effects. What the dual and multi-agonist clinical data shows.